ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,721.60
-1.06%
S&P ASX All Technology
3,063.30
-0.61%
Brent Oil
83.43
-0.16%
US Dollar vs AUD
1.51375
-0.45%
Bitcoin
61,972.96
1.29%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NovoCure Ltd (NVCR)

  7. NovoCure Ltd (NVCR) News

NVCR

NovoCure (NVCR)

NovoCure Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NVCR
DateTimeSourceHeadlineSymbolCompany
02/05/202421:01Business WireNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from PharmakonNASDAQ:NVCRNovoCure Ltd
02/05/202421:00Business WireNovocure Reports First Quarter 2024 Financial ResultsNASDAQ:NVCRNovoCure Ltd
25/04/202400:45Business WireResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024NASDAQ:NVCRNovoCure Ltd
05/04/202422:00Business WireNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:NVCRNovoCure Ltd
01/04/202422:00Business WireNovocure to Report First Quarter 2024 Financial ResultsNASDAQ:NVCRNovoCure Ltd
29/03/202411:07Business WireMETIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長NASDAQ:NVCRNovoCure Ltd
29/03/202404:51Business WireKlinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem LungenkrebsNASDAQ:NVCRNovoCure Ltd
29/03/202404:50Business WireL’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives..NASDAQ:NVCRNovoCure Ltd
27/03/202422:00Business WireMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerNASDAQ:NVCRNovoCure Ltd
11/03/202422:00Business WireINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGONASDAQ:NVCRNovoCure Ltd
06/03/202408:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
05/03/202410:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVCRNovoCure Ltd
05/03/202409:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVCRNovoCure Ltd
02/03/202409:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVCRNovoCure Ltd
02/03/202409:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVCRNovoCure Ltd
01/03/202408:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
01/03/202408:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
01/03/202408:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
01/03/202408:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
01/03/202408:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
22/02/202423:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NVCRNovoCure Ltd
22/02/202423:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVCRNovoCure Ltd
22/02/202423:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NVCRNovoCure Ltd
22/02/202423:00Business WireNovocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateNASDAQ:NVCRNovoCure Ltd
19/01/202403:10Dow Jones NewsNovocure Shares Rise 17% After FDA Accepts Pre-Market ApplicationNASDAQ:NVCRNovoCure Ltd
18/01/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVCRNovoCure Ltd
18/01/202423:00Business WireNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung CancerNASDAQ:NVCRNovoCure Ltd
13/01/202408:57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
12/01/202409:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
09/01/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVCRNovoCure Ltd
 Showing the most relevant articles for your search:NASDAQ:NVCR

Your Recent History

ASX
QBE
QBE Insurance
NYSE
XOM
Exxon Mobil
PM
XAUUSD
Gold vs US Dollar
FX
AUDJPY
AUD vs Yen
ASX
ANZ
Australia And New Zealan...
FX
AUDCAD
AUD vs CAD
CCOM
SILVER
SILVER
ASX
WOW
Woolworths
SPI
SP500
S&P 500
FX
EURAUD
Euro vs AUD
NASDAQ
QQQ
Invesco QQQ Trust Series 1
ASX
CSL
CSL
ASX
WDC
Westfield
ASX
ORG
Origin Energy
ASX
XTO
S&P ASX 100
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved